Correlation Between NLS Pharmaceutics and Enveric Biosciences

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both NLS Pharmaceutics and Enveric Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NLS Pharmaceutics and Enveric Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between NLS Pharmaceutics AG and Enveric Biosciences, you can compare the effects of market volatilities on NLS Pharmaceutics and Enveric Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NLS Pharmaceutics with a short position of Enveric Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of NLS Pharmaceutics and Enveric Biosciences.

Diversification Opportunities for NLS Pharmaceutics and Enveric Biosciences

0.32
  Correlation Coefficient

Weak diversification

The 3 months correlation between NLS and Enveric is 0.32. Overlapping area represents the amount of risk that can be diversified away by holding NLS Pharmaceutics AG and Enveric Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Enveric Biosciences and NLS Pharmaceutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NLS Pharmaceutics AG are associated (or correlated) with Enveric Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Enveric Biosciences has no effect on the direction of NLS Pharmaceutics i.e., NLS Pharmaceutics and Enveric Biosciences go up and down completely randomly.

Pair Corralation between NLS Pharmaceutics and Enveric Biosciences

Given the investment horizon of 90 days NLS Pharmaceutics AG is expected to generate 0.66 times more return on investment than Enveric Biosciences. However, NLS Pharmaceutics AG is 1.52 times less risky than Enveric Biosciences. It trades about 0.02 of its potential returns per unit of risk. Enveric Biosciences is currently generating about -0.06 per unit of risk. If you would invest  182.00  in NLS Pharmaceutics AG on December 27, 2024 and sell it today you would lose (29.00) from holding NLS Pharmaceutics AG or give up 15.93% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

NLS Pharmaceutics AG  vs.  Enveric Biosciences

 Performance 
       Timeline  
NLS Pharmaceutics 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in NLS Pharmaceutics AG are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, NLS Pharmaceutics may actually be approaching a critical reversion point that can send shares even higher in April 2025.
Enveric Biosciences 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Enveric Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

NLS Pharmaceutics and Enveric Biosciences Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with NLS Pharmaceutics and Enveric Biosciences

The main advantage of trading using opposite NLS Pharmaceutics and Enveric Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NLS Pharmaceutics position performs unexpectedly, Enveric Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enveric Biosciences will offset losses from the drop in Enveric Biosciences' long position.
The idea behind NLS Pharmaceutics AG and Enveric Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Complementary Tools

Transaction History
View history of all your transactions and understand their impact on performance
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
CEOs Directory
Screen CEOs from public companies around the world
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences